Maxigen Biotech Inc.

Informe acción TWSE:1783

Capitalización de mercado: NT$4.1b

Maxigen Biotech Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Ching-Ting Chen

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO2.8yrs
Participación del CEOn/a
Permanencia media de la direcciónsin datos
Promedio de permanencia en la Junta Directiva2.9yrs

Actualizaciones recientes de la dirección

Recent updates

Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Mar 28
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality

Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

Apr 22
Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?

We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Apr 01
We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings

Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 16
Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Feb 23
The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More

Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Feb 02
Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?

Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Jan 10
Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield

Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

Dec 14
Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?

If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Nov 22
If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ching-Ting Chen en comparación con los beneficios de Maxigen Biotech?
FechaCompensación totalSalarioIngresos de la empresa
Mar 31 2024n/an/a

NT$150m

Dec 31 2023n/an/a

NT$166m

Sep 30 2023n/an/a

NT$191m

Jun 30 2023n/an/a

NT$192m

Mar 31 2023n/an/a

NT$163m

Dec 31 2022n/an/a

NT$139m

Sep 30 2022n/an/a

NT$110m

Jun 30 2022n/an/a

NT$99m

Mar 31 2022n/an/a

NT$87m

Dec 31 2021NT$1mNT$540k

NT$88m

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Ching-Ting es razonable en comparación con empresas de tamaño similar en el mercado TW.

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Ching-Ting con los resultados de la empresa.

CEO

Ching-Ting Chen

2.8yrs

Permanencia

NT$1,322,000

Compensación

Ms. Ching-Ting Chen serves as Head of Research & Design Center at TCI Co., Ltd. since February 5, 2020. She served as R&D chief, TCI Co., Ltd.She holds Master’s Degree in Chemistry, National Taiwan Univer...

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Ching-Ting Chen
GM & Representative Director2.6yrsNT$1.32msin datos
Yung-Hsiang Lin
Chairman of the Board2.9yrssin datossin datos
Tsiu-Yuan Li
Representative Director9yrssin datossin datos
Chen-Chen Fu
Representative Director2.9yrssin datossin datos
Song Yuan Liao
Independent Director2.9yrssin datossin datos
Shi-Ming Li
Independent Director2.9yrssin datossin datos
Zeng Zhong Ming
Independent Director2.9yrssin datossin datos
Tsong-Jieh Chiou
Directorno datasin datossin datos
Shih-Ming Lai
Directorno datasin datossin datos

2.9yrs

Permanencia media

Junta con experiencia: La junta directiva de 1783 no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.